Skip Navigation

European Journal of Heart Failure 2007 9(10):1070-1073; doi:10.1016/j.ejheart.2007.09.005
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (25)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cleland, J. G.F.
Right arrow Articles by Clark, A. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cleland, J. G.F.
Right arrow Articles by Clark, A. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society of Cardiology

Clinical trials update from the European Society of Cardiology Congress 2007: 3CPO, ALOFT, PROSPECT and statins for heart failure

John G.F. Cleland, Ahmed Tageldien Abdellah, Olga Khaleva, Alison P. Coletta* and Andrew L. Clark

Department of Cardiology, University of Hull, Castle Hill Hospital Cottingham, Kingston-upon-Hull, HU16 5JQ, UK

* Corresponding author. Tel.: +44 1482 624086; fax: +44 1482 624085. E-mail address: a.p.coletta{at}hull.ac.uk (A.P. Coletta).


  Abstract

This article provides information and a commentary on trials relevant to the pathophysiology, prevention and treatment of heart failure, presented at the European Society of Cardiology Congress 2007. Unpublished reports should be considered as preliminary data, as analyses may change in the final publication.

In the 3CPO study, non-invasive ventilation produced a more rapid resolution of symptoms in patients hospitalised with acute cardiogenic pulmonary oedema; but had no effect on survival, compared to standard oxygen therapy. The ALOFT study showed that the selective oral renin inhibitor aliskiren reduces plasma BNP levels and is well tolerated in patients with heart failure receiving ACE inhibitors or ARBs, although the study was not powered to show clinical benefit. In the PROSPECT study, no echocardiographic measure of mechanical dyssynchrony was identified that was useful for identifying patients more or less likely to respond to CRT. Low dose atorvastatin reduced the incidence of sudden cardiac death in a small placebo controlled study of patients with advanced chronic heart failure.

Key Words: Randomised controlled trials • heart failure

Received September 12, 2007; Accepted September 13, 2007


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur J Heart FailHome page
A. P. Coletta, D. Cullington, A. L. Clark, and J. G.F. Cleland
Clinical trials update from European Society of Cardiology meeting 2008: TIME-CHF, BACH, BEAUTIFUL, GISSI-HF, and HOME-HF
Eur J Heart Fail, December 1, 2008; 10(12): 1264 - 1267.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
K. Dickstein, A. Cohen-Solal, G. Filippatos, J. J.V. McMurray, P. Ponikowski, P. A. Poole-Wilson, A. Stromberg, D. J. van Veldhuisen, D. Atar, A. W. Hoes, et al.
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)
Eur J Heart Fail, October 1, 2008; 10(10): 933 - 989.
[Full Text] [PDF]

Home page
 Eur J Heart FailHome page
S. Chattopadhyay, M. F. Alamgir, N. P. Nikitin, A. G. Fraser, A. L. Clark, and J. G.F. Cleland
The effect of pharmacological stress on intraventricular dyssynchrony in left ventricular systolic dysfunction
Eur J Heart Fail, April 1, 2008; 10(4): 412 - 420.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
A. Auricchio and F. F. Faletra
Mechanical dyssynchrony in CRT patients: Still searching for the Holy Grail!
Eur J Heart Fail, March 1, 2008; 10(3): 217 - 219.
[Full Text] [PDF]

Home page
 Eur J Heart FailHome page
S. J. Cazeau, J-C. Daubert, L. Tavazzi, G. Frohlig, and V. Paul
Responders to cardiac resynchronization therapy with narrow or intermediate QRS complexes identified by simple echocardiographic indices of dyssynchrony: The DESIRE study
Eur J Heart Fail, March 1, 2008; 10(3): 273 - 280.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
B. W.L. De Boeck, M. Meine, G. E. Leenders, A. J. Teske, H. van Wessel, J. H. Kirkels, F. W. Prinzen, P. A. Doevendans, and M. J. Cramer
Practical and conceptual limitations of tissue Doppler imaging to predict reverse remodelling in cardiac resynchronisation therapy
Eur J Heart Fail, March 1, 2008; 10(3): 281 - 290.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
J. G.F. Cleland, A. P. Coletta, A. T. Abdellah, D. Cullington, A. L. Clark, and A. S. Rigby
Clinical trials update from the American Heart Association 2007: CORONA, RethinQ, MASCOT, AF-CHF, HART, MASTER, POISE and stem cell therapy
Eur J Heart Fail, January 1, 2008; 10(1): 102 - 108.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.